Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Aytu Biopharma (AYTU) Liabilities from Discontinued Operations: 2024

Aytu Biopharma's Liabilities from Discontinued Operations was N/A to $557,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $557,000, marking a year-over-year change of. This contributed to the annual value of $557,000 for FY2024, which is N/A change from last year.
As of Q2 2024, Aytu Biopharma's Liabilities from Discontinued Operations stood at $557,000.
Aytu Biopharma's Liabilities from Discontinued Operations' 5-year high stood at $557,000 during Q2 2024, with a 5-year trough of $557,000 in Q2 2024.
Moreover, its 1-year median value for Liabilities from Discontinued Operations was $557,000 (2024), whereas its average is $557,000.